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Abstrak 
 
siRNA (small interfering ribonucleic acid) adalah sebuah metode yang dapat digunakan untuk mengatasi infeksi 
virus yang prinsip kerjanya berdasarkan metode komplementer dsRNA (double stranded RNA) pada RNA virus 
sehingga menyebabkan kegagalan proses transkripsi (silencing).  Untuk lebih memahami bagaimana proses kerja 
dan ulasan penelitian siRNA yang terkini, di dalam tulisan ini ditinjau siRNA sebagai metoda yang dikembangkan 
untuk mengatasi infeksi dan meneliti efeknya pada replikasi beberapa virus seperti Hepatitis C, Influenza, Polio, 
dan HIV. Kami menemukan bahwa urutan basa nukleotida dari target siRNA sangat penting. Hal tersebut harus 
homolog dengan target RNA virus dan tidak menganggu RNA sel inang. Untuk mengurangi kegagalan terapi 
siRNA oleh adanya mutasi, digunakan beberapa siRNA yang sekaligus menjadi target RNA virus yang berbeda. 
Namun demikian, terapi siRNA masih menghadapi beberapa kesulitan seperti pengiriman (transfer) khusus ke 
jaringan yang terinfeksi dan perlindungan siRNA dari perusakan oleh nuklease. Berdasarkan beberapa penelitian 
yang telah dilakukan, siRNA dapat digunakan sebagai alternatif untuk mengobati infeksi yang disebabkan oleh 
virus. Terapi tersebut direkomendasikan untuk dilakukan uji klinis dengan memperhatikan beberapa aspek seperti 
desain siRNA dan mekanisme transfer. (Health Science Indones 2010; 1: 58 - 65) 
Kata kunci: siRNA, infeksi virus, target virus, alternatif terapi 
Abstract 
SiRNA is a promising method to deal with viral infections. The principle of siRNA is based on the 
complementarily of (synthetic) dsRNA to an RNA virus which, in consequence, will be silenced. Many studies 
are currently examining the effects of siRNA on replication of diverse virus types like Hepatitis C, polio and HIV. 
The choice of the siRNA target sequence is crucial. It has to be very homologous to the target RNA, but it cannot 
target RNA of the host cell. To reduce the possibility for the virus to escape from the siRNA therapy by mutating, 
multiple siRNAs have to be used that target different sequences of the viral RNA. Still, siRNA therapy is facing 
some difficulties such as the specialized delivery to the infected tissue and the siRNA protection from the 
digestion by nucleases. These problems will have to be solved before siRNA therapy could be used in clinical 
trials.. Based on several researches, siRNA could be used as an alternative therapy against life threatening viruses. 
This therapy is recommended to be tested further in clinical trials with respect to several aspects, such as design of 
siRNA and transfer mechanism. (Health Science Indones 2010; 1: 58 - 65) 
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The discovery of the RNA interference (RNAi) 
mechanism took place in 1998
1
 for which a 
Nobel Prize was awarded. RNAi is a specific 
gene silencing process based on RNA 
homology. The homologous RNA sequences 
form double-stranded RNA (dsRNA). Subse-
quently, dsRNA triggers destruction and thereby 
gene activity is suppressed.
2
 This process was 
initially observed in plants as a conserved 
defense mechanism against viral infections
2 
and 
foreign nucleic acids.
3
 After the discovery of the 
RNAi mechanism, it was used in functional 
genomics studies of model organisms, 
Drosophila melanogaster
4
 and Caenorhabditis 
elegans
5 
to silence the activity of the gene of 
interest.  
Currently, RNAi has becomes a powerful tool in 
medicine as a method to silence genes 
responsible for cancer and neurodegenerative 
diseases.
6,7 
Now, a new siRNA application has  
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arise to become a cure or vaccination against 
life threatening viruses like HIV or Hepatitis C.  
In current studies aiming to inhibit the viral 
replication, small interfering RNA (siRNA) is 
used in order to guide the RNAi mechanism. 
The siRNA therapy against viral infections aims 
to inhibit the viral replication, thereby curing 
infected tissue, restoring cell functions and 
limiting the symptoms caused by virus 
infection. SiRNA can also be used as 
vaccination, by preventing the entrance of the 
viral particle into the cell. However, to outline a 
good siRNA antiviral therapy, the knowledge of 
the virus life cycle has to be gained.  
This article reviews the important aspects of 
which siRNA therapy has to fulfill to effectively 
inhibit viral replication. We also review the 
available research reports including the 
advantages and disadvantages of the method in 
targeting the viral infections.  
The pathway of siRNA  
siRNA duplexes consist of approximately 21 
nucleotides and can induce gene silencing 
through sequence specific cleavage of perfectly 
complementary messenger RNA (mRNA).
8
 In 
the natural RNAi mechanism, dsRNA is 
recognized and cleaved by a Dicer enzyme 
complex into siRNA. Next, siRNA is incor-
porated into Argonaute 2 (AGO2) and the 
RNAi-induced silencing complex (RISC), 
which checks for complementarily. If the short 
dsRNA is perfectly matched, AGO2 cleaves the 
dsRNA into a sense (coding) and an antisense 
(non-coding) strand. In consequence, RISC, 
containing the antisense strand, is produced. 
The RISC and RNA antisense strand are now 
forming an activated complex that recognizes 
the target sites and cleaves the target mRNA.
8
 A 
simplistic overview of RNAi mechanism 
involving siRNA is shown in Figure 1.
8
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. A simplistic overview of the RNA interference pathway. 
As mentioned before, siRNA can be used as a 
cure against viruses. There are already some 
siRNA therapy trials for viral infections. Some 
of those therapies were tested in vitro and there 
are still some problems that have to be resolved 
before starting in vivo experiments. Other 
therapies have been examined in vivo either on 
model organisms or infected cell cultures and 
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gave promising results. Although all of the 
discussed siRNA aspects are important in 
making antiviral cures, the efficiency of the 
cure depends on the virus type and its further 
properties. Here we discuss some examples of 
viruses given corresponding siRNA antiviral 
therapies.  
Cytomegalovirus (CMV) retinitis 
CMV retinitis, also known as cytomegalovirus 
retinitis is a DNA virus which causes retinal 
inflammation that can lead to blindness.
9
 The 
siRNA efficiency in the eye was demonstrated 
in animal models.
10
 The siRNAs can be 
delivered directly to the target tissue, by means 
of intravenous injection. The advantages of the 
local delivery in siRNA therapy is the lower 
dose required for efficient silencing, because of 
the reduced exposure to nucleases. 
Additionally, the risk of siRNA systemic 
exposure declines by more specific application 
of a drug.
8
 This siRNA therapy has an 
advantage over the recently given antivirals, 
because, once siRNA is activated in the cell, it 
can be active for weeks in non-dividing cells. 
Thus, the antivirals do not have to be given 
daily to the patient, but only once in few weeks.               
Avian influenza A (H5N1 virus) 
The avian influenza virus H5N1 (AIV), also 
known as ‘bird flu’, infects the epithelial cells 
of the upper respiratory tract and lungs. SiRNA 
which targets the specific conserved regions of 
the viral genome, such as the PA (polymerase 
acid), PB1 (polymerase basic 1) and NP 
(nucleoprotein) gene, could be the solution.  
Recent tests
11
 showed that siRNA could indeed 
inhibit the viral reproduction. The siRNA that 
silences the PA and PB1 genes slightly 
inhibited the viral reproduction, whereas the 
siRNA targeting NP gene inhibited about 70% 
of the virus reproduction. This test was 
performed in cell cultures. To confirm the 
effectiveness of siRNA, not only in vitro but 
also in vivo, mice infected with the avian 
influenza virus were treated with siRNA. Also 
there was a significant inhibition in viral 
replication in the lungs of the mice, when they 
were treated with the siRNA directed to the NP 
gene. Furthermore, when the mice received 
treatment with a lethal dose of the H5N1 virus 
and were treated with the siRNA against the NP 
gene, 2 of the 8 mice were protected, while in 
the control group all the mice died.
11 
Based on this study, it can be concluded that 
siRNA therapy is promising in the treatment of 
AIV. Targeting conserved viral sequences like 
the NP gene would reduce the need of inventing 
new drug almost every year. However, the 
efficiency of this therapy has to be improved. It 
can be achieved for example by using combined 
siRNA targeting both the NP and PA genes.
11
  
Polio virus 
The polio virus is still a severe threat in 
developing countries, causing poliomyelitis that 
leads to paralyses and sometimes even death. 
An experiment performed by Gitlin et al
12
 
showed almost complete inhibition of the viral 
replication by siRNA against the polio virus in 
human cells.
12
 In the experiment, two different 
siRNAs were tested separately. One siRNA 
silenced the viral protein 3 and the other 
designed to cleave mRNA coding for the 
polymerase gene (3D). Tests performed with 
single siRNA type were less efficient and the 
protective effect of siRNA on cells infected 
with the polio virus did not last 24 hours. 
Twenty four hours after the infections were 
treated with polio virus and the treatment with 
the siRNA, 75 % of the cells were viable again 
for the infection. Sequence analysis revealed 
that silent point mutation had occurred. 
However, when a mixture of siRNA molecules 
was used, no escaping viruses were observed.
12 
Another study described combined siRNA cure 
for persistent poliovirus
13
 found total inhibition 
of viral replication. In this study, performed on 
human cell culture, combined siRNA was 
added four times to ensure that every cell 
infected with the virus would also be 
transfected with siRNA. After four siRNA 
treatments, no recovery of virus had been found 
and thus the cell cultures had been completely 
cured.
13
  
Those experiments showed that the use of 
combined siRNAs significantly reduced the 
viral mutation rate. The study also showed that 
a complete cure of virus with siRNA is 
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possible.
13
 The main problem is that combined 
siRNA treatment has to be effectively delivered 
to the infected cells. Therefore siRNA delivery 
systems have to be improved.  
Hepatitis C Virus 
The Hepatitis C virus (HCV) causes severe 
infection in the liver leading to the development 
of chronic hepatitis, and potentially even 
cirrhosis and hepatocellular carcinoma.
2
  
Unfortunately, there is no vaccine available for 
HCV. Current treatment for HCV, consisting of 
administering pegylated interferon α and 
ribavirin, has limited efficiency against certain 
types of HCV and has many side effects. 
However, siRNA that specifically targets HCV 
IRES within the 5’ NTR has been tested.2  
An experiment by Chevalier et al,
2 
 showed that 
indeed viral replication was inhibited by 
siRNA. A good candidate for the siRNAs to 
target against was the HCV IRES region, since 
this region is essential for the initiation of 
polyprotein translation and is conserved in 
many HCV types. The problem with this region 
was that it harbors strong secondary and tertiary 
structures, which are difficult for the siRNA to 
target, though not impossible. Five different 
siRNAs were proved to inhibit the replication. 
Even in experiments with replicon-containing 
cells, the five siRNAs left showed that they 
strongly inhibited the viral RNA replication and 
three of these siRNAs even abolished the virus. 
In contrast, a study done by Yokota et al,
14 
 
showed that some siRNA increased the 
replication rate instead of decreasing it. This 
shows that the right target sequence is essential 
and many siRNAs have to be tested. 
Additionally, a perfect base-pairing between the 
viral RNA and the siRNA is required for the 
most effective silencing. Only two small 
mismatches, wobble base-pairs, were tolerated 
by the most effective siRNAs. Other 
mismatches were not tolerated; this illustrates 
the specificity of the siRNA and explains why 
some HCV infected cell could escape from the 
siRNA treatment under pressure, like antiviral 
treatments. This study showed again that a 
single siRNA treatment is not that effective. To 
optimize the effectiveness of the siRNA, a 
multiple siRNA treatment has to be used. The 
study by Yokota et al,
14 
additionally 
demonstrates that siRNA sequences have to be 
chosen very precisely to ensure gene silencing.  
Human Immunodeficiency Virus (HIV) 
Belonging to retroviruses, HIV attacks the T-
cells of the immune system.  HIV infections are 
currently treated with highly active 
antiretroviral therapy (HAART).
15
 The HAART 
therapy consists of multiple antiretroviral 
agents, keeping the amount of HIV low, but it 
cannot cure the HIV patient nor remove all 
symptoms.
15 
Next to it, antivirals cause various 
side effects and not all of them can be 
combined.  
The use of siRNAs in HIV therapy brings new 
perspectives. It could reduce side effects and 
efficiently silence the HIV. However, HIV is a 
type of virus where the genome mutates very 
rapidly and so does the siRNA target site.
3 
Son 
et al,
15 
described a treatment of HIV transfected 
cells which were treated with bi-specific 
constructs. More than 90% viral inhibition has 
been observed with two different siRNAs. It 
suggests that the viral escape can be overcome 
by using combinatorial siRNAs against 
conserved sequences especially those that allow 
wobble-base pairing. This method would be 
effective and could be used as a complete HIV 
cure only in the early stage of HIV infection, 
when the viral genome has not yet integrated 
into the genome of the host. When the viral 
genome has integrated into the host genome, 
the virus cannot be completely cleared. 
Although it is possible to inhibit viral 
replication by siRNAs, the viral genome will 
never be completely removed from the host. 
Summarizing, when the viral genome has 
integrated into the host genome, the siRNA 
therapy would have to be given for the rest of 
the patient’s life.15 
A different problem with HIV is that effective 
siRNA treatment required siRNA delivery to 
every infected cell in order to effectively kill 
the virus. If this is not the case, the chance of 
mutation and escaping is much bigger. In the 
case of HIV, CCR5, a chemokine receptor, can 
be a good target for siRNA, because cells with 
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no CCR5 membrane-proteins are resistant 
against HIV infection and have no abnormal 
phenotype. In a test with siRNA against CCR5 
and p24, which makes up the viral capsid, the 
virus production was completely eliminated.
15
 
By making cells less susceptible for HIV 
infection this method could be used in the 
future as HIV vaccination. 
The effect of mutation  
The main problem with current therapies 
against (human life threatening) viruses is the 
high mutability of the virus. Viral high 
mutation rates are caused by the leak of DNA 
polymerases which can find and fix mistakes in 
the viral genome. The mutations in the viral 
genome can be fatal for the viral replication, but 
they also can become a tool in escaping 
antiviral treatments. Despite high mutation rates 
in the viral genome, it still seems to be a good 
target for siRNA therapy. It has been shown by 
Haasnoot et al, 
16
 that the most effective siRNA 
will complement with a highly conserved 
sequence in the viral genome. The chance of a 
mutation in highly conserved regions is smaller, 
because it would affect viral fitness. Therefore, 
targeting conserved regions of the viral genome 
reduces the possibility of viral escape by 
mutation. An additional option to reduce viral 
escape is a combined use of multiple siRNAs, 
targeting more than one viral genome fragment. 
There are examples have shown that using two 
different siRNAs can significantly inhibit or 
totally block the viral replication.
15,17
 Using 
combined siRNA, it is harder for the virus to 
escape silencing, because all sequences targeted 
by siRNA have to be mutated.
16
 There are, 
however, more strategies for the virus to escape 
from the siRNA treatment. First, the virus can 
replicate in compartments in the cell that are 
inaccessible to the siRNA, the nucleus for 
example, and possibly even stay there. Also 
viral RNA bound to proteins or double-stranded 
viral RNA are inaccessible for the siRNA-
machinery.
16 
A single point mutation, substitution or deletion 
seems to be enough for the RNA to not be 
recognized by siRNA. The deletion can induce 
an inaccessible RNA structure for the siRNA. 
When it comes to substitutions, the mismatches 
can be more or less accepted by AGO2 and the 
RISC complex if they are at certain positions. 
Also the mismatches between A:C are less 
likely to result in loss of silencing than U:G 
mismatches.
17
 Not all the point mutations are 
acceptable for the siRNA-machinery. To escape 
from silencing by siRNA, the point mutations 
do not have to occur in the specific target 
sequence. It is possible that mutations outside 
of targeted region change the secondary 
structure of the RNA, making it impossible for 
the siRNA to reach the target sequence of viral 
RNA.
17 
Design of siRNA 
The design of siRNA has to fulfill some 
conditions to efficiently inhibit expression of 
targeted host or virus genes. First of all, 
previous studies
17 
have established that highly 
functional siRNA had a G:C content between 
32 and 52%. Secondly, low internal stability of 
siRNA at the 5’ antisense end is also crucial for 
effective silencing and efficient entry into 
RISC. To ensure low internal stability, 5’ 
antisense end has to have a high A:U content. 
Next to it, the siRNA target sequence cannot 
contain internal repeats or palindrome 
sequences. Palindrome sequences form internal 
fold back structures reducing effective 
concentration and silencing the potential of 
siRNA. Therefore, siRNA has to have high 
internal stability and a good indicator for this is 
a low melting temperature. Also, the target 
sequence is important. As already mentioned, 
the eventual mutations are more accepted at 
certain positions than others. Therefore an 
algorithm has to be made in which the crucial 
positions of the targeted sequences have to be 
estimated.
17 
SiRNA stabilization against nucleases 
The siRNA therapy faces yet another problem. 
It is known that siRNA duplexes are highly 
unstable in serum with a half-life time of 
minutes.
8
 This rapid siRNA breakdown is 
caused by the activity of nucleases. To make an 
efficient siRNA treatment and improve its 
pharmacokinetic properties, siRNA duplexes 
have to be resistant against nuclease activity. 
This can be done by either introducing a 
phosphorothioate (P=S) backbone linkage at 3’ 
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ends or by introducing internal 2’ sugar 
modifications like 2’-O-methyl or 2’-deoxy-2’-
fluoro.
20
 The structures of modified RNAs are 
shown in figure 2. 
 
 
Figure 2.The modification of sugars in nuclease resistant RNA.
19
 Unmodified RNA (B) RNA with 
phosphorothioate backbone linkage (C) RNA with internal 2’-O-methyl-ribose modification 
(D) RNA with internal 2’-deoxy-2’-fluoro-ribose modification. 
 
Although the internal sugar modifications are 
generally well tolerated, the exact modification 
position within the siRNA duplex seems to be 
crucial for the preservation of siRNA function. 
To identify minimal modifications, required for 
siRNA nuclease resistance, the nuclease 
degradation fragments of siRNA can be 
studied.
8
 It has been previously established that 
nuclease resistant siRNAs displayed in vivo 
improved pharmacokinetics when administered 
in nuclease rich environments, like blood.
20
 
However, if siRNAs are delivered to less 
nuclease rich environments, like lungs, or the 
exposure to nucleases is minimized by packing 
siRNA in liposomes, the nuclease stabilization 
will be reduced to minimum.
8
 The nuclease 
stabilization has also no influence on the 
stability of siRNA inside the cell. Because the 
silencing effect caused by siRNA in non-
dividing cell can last for weeks, the intracellular 
siRNA stabilization is not necessary.
21 
SiRNA delivery to infected cells 
To make siRNA an effective inhibitor of virus 
replication in in vivo setups, cells already 
infected with the virus have to be reached. A 
good delivery system is also required to reduce 
viral infections. Here we mention several types 
of delivery systems.  
Local delivery 
Local delivery is the simplest option to deliver 
naked siRNA. When siRNA is injected or 
administered near the target tissue, the effective 
dose of siRNA is lower and in consequence 
reduces undesirable systemic side effects. 
However, this method is only efficient in the 
case of viral infections of easily accessible 
organs like eye or lungs, but not in the case of 
liver or kidney viral infections. To target siRNA 
to other tissues, delivery requires more 
sophisticated methods.
8 
Conjugation 
One of the more cell-type specific delivery 
methods is conjugation. It involves a covalent 
attachment of siRNA to a targeting molecule. 
This method is attractive for siRNA delivery, 
because only one strand of the duplex is active 
and the targeting molecule can be easily 
attached to the sense strand without affecting 
the activity of the antisense strand which is 
incorporated into the RISC-complex. A well 
known example in vivo silencing mechanism is 
the conjugation of siRNA to cholesterol aiming 
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to target the liver.
22, 23 
For delivery to specific 
cell types, siRNA can also be conjugated into 
RNA aptamers. RNA aptamers are fragments of 
RNA synthetically designed to recognize cell-
type-specific membrane antigens. Aptamers 
promote specific cellular uptake and cause 
RNAi mediated target silencing. In theory it is 
possible to design RNA aptamers for every cell 
type. Although short aptamers (22- 35 bases) do 
work for local delivery in vivo, they will be 
quickly cleared by the kidney and thus the 
siRNA half-life would be too short for systemic 
therapy. This problem could be solved by using 
longer RNA aptamers (45-55 bases). However, 
long RNA molecules may be difficult to 
synthesize on a commercial scale.
23
  
Liposomes 
Another option to deliver siRNA to cells of 
concern is by using liposomes, which consist of 
a phospholipid bilayer enclosing the aqueous 
compartment with siRNA. Liposomes can fuse 
with a specific cell membrane, which is 
determined by the composition of the 
phospholipid bilayer of the vesicle. The most 
successful example of delivery siRNA using 
liposomes is targeting the liver tissue. Although 
a lipid based delivery system of siRNA 
represents a promising perspective, there are 
primary cell types, like lymphocytes, which are 
resistant to lipid-mediated transfection.
8 
Polyethylenimine I (PEI) 
It is also possible to transfer siRNA using 
cationic peptides and polymers. siRNA interacts 
with these positively charged peptides by ionic 
interactions between negatively charged 
phosphate backbones to form stable 
nanoparticles. The most impressive example of 
this type of siRNA delivery is PEI. PEI has a 
synthetic, linear or branched structure with high 
cationic charge densities. The polyplexes 
formed by PEI and siRNA are thought to 
interact with the cell surface electrostatically 
and are transported into the cells by 
endocytosis. Subsequently, in the endosome, 
PEI acts like a proton sponge, disrupting 
endosomal pH, causing an increased influx of 
protons and water into the endosome. In 
consequence, the endosome swells up and 
finally the polyplexes of siRNA and PEI are 
released into the cytoplasm.
24 
Although this 
delivery method turned out to be successful in 
against influenza infection in mice,
25
 it turned 
out to be extremely toxic in higher doses. 
Currently, optimizing PEI physical structure to 
improve in vivo siRNA delivery is in progress.   
In conclusion, that siRNA therapy has serious 
advantage over other antiviral therapies. 
However, the siRNA target sequence has to be 
homologous enough to inhibit viral replication. 
It cannot overlap with mRNAs coding for host 
cell essential structures and is protected from 
digestion by nucleases. In addition, it is obvious 
that several aspects of siRNA therapy have to be 
improved, such as a delivery system or virus 
target sequences. Nevertheless, the arising 
possibilities of siRNA therapy as antiviral 
agents or vaccination are astonishing.  
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